|Last Price||Today's Change||52-Week Range||Trading Volume|
|69.93||-0.72 (-1.02%)||64.01 - 77.31||9.9 million (Above Avg)|
Market data as of 4:01PM 06/30/15. Quotes are delayed by at least 15 min.
MM-398 Receiving the Priority Review Designation by US FDA for New Drug Application and the Acceptance of Market Authorization Application by EMA in Post-Gemcitabine Metastatic Pancreatic Cancer
06/25/2015 3:18 PM ET
U.S. FDA Grants Priority Review for MM-398 New Drug Application
06/25/2015 7:00 AM ET